Perrigo Continues Overhaul Adding HRA Pharma, Boosts Chances For OTC Oral Contraceptive In US

HRA’s approval for pharmacy sales of a daily oral contraceptive the UK and its ongoing work on an NDA to propose making another progestin-only contraceptive ingredient available OTC in the US stand out as additions to Perrigo’s business with the most substantial revenue impacts.

• Source: Alamy

Pharma industry weight behind making daily oral contraceptives available OTC in the US gains substantial heft with Perrigo Company PLC’s planned acquisition of French firm HRA Pharma, which recently received UK approval for nonprescription sales of a daily-use progestin-only contraceptive.

With its acquisition of HRA, officially identified in France as Héra SAS, for €1.8bn ($2.1bn) in a cash deal announced...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Rx-to-OTC Switch

More from Health